THE NICHOLAS CONOR INSTITUTE
                                            for Pediatric Cancer Research
Building Better Therapies for Children


The Nicholas Conor Institute and its partners will provide a highly integrated research platform to:
  • Research the causes of childhood cancers with specific focus on discovering cancer- specific  therapeutic and diagnostic targets
  • Discover, validate and develop diagnostic and prognostic biomarkers that will guide the physician to select individualized therapies
  • Develop a screening and molecular profiling platform to monitor cancer and patient physiology allowing rational guidance of therapies
  • Monitor the efficacy and toxicity of therapies in pediatric cancer patients.
COLLABORATIVE EFFORTS:


BIOMEDICAL INDUSTRY PARTNERS

GeneKey and The Nicholas Conor Institute are excited to announce a partnership to apply GeneKey’s personalized research approach to childhood cancers. As part of this partnership, patients will receive personalized therapy based upon the best available science, and researchers will continuously test and refine their models of childhood cancer biology and therapeutics based on the resulting clinical responses.

GeneKey offers a unique personalized research program that helps guide therapy decisions for cancer patients and their oncologists based on the molecular and genomic characteristics of their specific cancer. Our researchers use state-of-the-art genomic technologies as well as proprietary bio-computational tools to extract molecular information from patient biopsies, and then conduct full mechanistic analyses to potentially link a specific cancer to particular mechanisms and then to relevant therapies. Unlike other approaches in personalized medicine that focus on a limited set of cancer drugs, we look at hundreds of marketed drugs as well as investigational drugs for a potential match to patients’ specific cancer.

    "GeneKey is honored to partner with The Nicholas Conor Institute to battle the scourge of childhood cancer. We are very impressed with The Nicholas Conor Institute’s business and scientific approach to identify and develop both innovative therapies and original diagnostics for childhood cancer. We believe this partnership will accelerate our goal of enabling real-time bedside-to-bench medicine - providing results for today's patients based on personalized analysis while culling the learnings to apply to other patients."
                                          - Raphael Lehrer, Ph.D.,
                                             President and Chief Scientist



AltheaDx is bringing theranostics into clinical use. Our labs are located in a 20,000 sq. ft. building in San Diego, California, with service operations for biopharma customers in compliance with GLP and CLIA requirements. The company has several key patents and technology affiliations with a variety of industry and academic institutions, including: NIH, NCI, UCSD, Sidney Kimmel Cancer Center, MD Anderson, and Memorial Sloan Kettering. We have a track record of reducing the time, risk, and cost of drug development by providing biomarker discovery and development to biopharma clients and clinical testing services to physicians.
 
Our proprietary gene expression profiles include quantitative assays for diagnosis of pediatric cancers, specifically Small Round Blue Cell Tumors that are often difficult to differentiate.  Our goal is to fully validate these tests through industry collaborations and to make them widely available for diagnosis and treatment of these rare diseases.

We see great opportunity in working with TNCI to bring both awareness and resources for further development and validation of quantitative diagnostic tests. Through collaboration, AltheaDx will identify key partners and critical resources to enable utility of appropriate tests for diagnosis and treatment of childhood cancers.  AltheaDx’ commitment to diagnostics excellence combined with TNCI’s focus will ultimately help in translation of clinically useful information for physicians and patients alike.

 AltheaDx has been working with the NIH on diagnostic tests for childhood cancers for over three years. This effort has resulted in published data and notice of approval from many in the industry, including the Children’s Oncology Group.  However, the test is still not broadly available.  We believe that TNCI’s commitment and awareness campaign will help deliver the much needed resources and clinical samples that are required to launch this test nationally.


STRATEGIC PARTNERS


The mission and promise at the Children’s Rare Disease Network is to improve, extend and save the lives of children living with a rare disease or disorder.  The  Children’s Rare Disease Network will accomplish this by harnessing the power of the patients and the patient advocates, by building a comprehensive a comprehensive web community and collaborative platform that will empower these patients, their families and caregivers to make a difference in the lives of their child, their therapy and treatments.

The Children’s Rare Disease Network is honored to work with The Nicholas Conor Institute and its co-founder Dr. Beth Anne Baber, who serves as an advisor to our organization. Rare Disease is defined as affecting 1 – 200,000 individuals.  Cancer in children is also rare, affecting 13,000 in the United States annually.  It is our goal and the goal of The Nicholas Conor Institute to help create greater public awareness about the prevalence of rare disease and its impact on our children, family and friends.  The Nicholas Conor Institute is involved with the Children’s Rare Disease Network because they understand that coming together as one community will ultimately make our efforts much more affective – there is power in numbers.

   "The Children’s Rare Disease Network believes that the mission and goals of The Nicholas Conor Institute to develop safer treatments for children is critical, not only for the cancer community, but for the broader rare disease community as a whole.  Their innovative approach to treatment development will unquestionably become a new standard in care for all sick children."
                     -Nicole Boice, Founder and CEO, The Project: Children's Rare Disease Network

The Nicholas Conor Institute
3525 Del Mar Heights Road, #946
San Diego, California 92130
(858) 227-9109